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Pandemic H1N1 Flu Infection
Pandemic H1N1 influenza of swine origin is a novel influ-
enza strain that causes a generally mild respiratory ill-
ness but results in severe disease or death in vulnerable
individuals. Chan et al (Am J Pathol 2010, 176:1828–
1840) compared the tropism and host responses of pan-
demic H1N1 to seasonal flu as well as to highly patho-
genic avian influenza strains. They found that in contrast
to seasonal flu, pandemic H1N1 and highly pathogenic
avian flu could infect the conjuctiva in the eye, suggest-
ing an additional route of transmission as well as differ-
ences in receptor binding profile. However, pandemic
H1N1 did not differ from seasonal flu either in replication
in respiratory cells or in induction of the host inflammatory
response. Taken together, these results are consistent
with epidemiological data suggesting that although pan-
demic H1N1 has subtle differences in transmissibility and
pathogenesis from seasonal flu, it does not induce the
pathogenic severity of avian flu viruses.
Preclinical Model of Primary Prostate Cancer
Despite earlier detection and treatment of prostate can-
cer, novel biomarkers are needed to discriminate be-
tween aggressive and indolent tumors. Priolo et al (Am J
Pathol 2010, 176:1901–1913) therefore generated a pre-
clinical xenograft model of human prostate cancer that
mimics the genetic and growth behavior of primary tu-
mors. In their model, xenografts maintained both the
histological and genetic characteristics of the parent tu-
mor. High proliferation rate, but not pathological stage or
Gleason score, determined whether the tumor would en-
graft in the murine host. In addition, measurement of
prostate-specific antigen levels correlated with tumor en-
graftment, but not engraftment of normal prostate tissue,
in these mice. Thus, this model should provide a platform
for biomarker and drug discovery in prostate cancer.
DLL4 (Delta-Like Ligand 4) Is a Prognostic
Factor for Early Breast Adenocarcinoma
DLL4, a Notch ligand expressed on the endothelium, is
regulated by vascular endothelial growth factor (VEGF)
and hypoxia, suggesting a possible role in tumor angio-
genesis and tumor growth. To explore the role of DLL4 in
breast cancer and its association with inflammatory mark-
ers, Jubb et al (Am J Pathol 2010, 176:2019–2028) per-
formed tissue microarrays and tumor immunohistochem-
istry on adenocarcinomas, normal breast tissues, and
angiosarcomas. They found that DLL4 was expressed
in intratumoral endothelial cells of breast adenocarci-
nomas, but not in nonlactating breast tissue, and that
high expression levels of DLL4 predicted poor prog-
nosis regarding both overall and relapse-free survival.
Assessing which patients express DLL4 may therefore
may be used to predict patients’ responsiveness to
anti-VEGF therapies.
Blocking EphB4 Impedes Angiogenesis and
Tumor Growth
The receptor tyrosine kinase EphB4, which is expressed
in many epithelial cancers, plays a key role in angiogen-
esis. Krasnoperov et al (Am J Pathol 2010, 176:2029–
2038) developed two monoclonal antibodies against
EphB4 that inhibit angiogenesis and tumor growth by two
distinct mechanisms. The mAb131, which binds the fi-
bronectin-like domain 1 of EphB4, inhibits endothelial
tube formation in vitro and tumor growth in vivo by induc-
ing degradation of human EphB4. In contrast, although
mAb147 does not degrade EphB4, it inhibits angiogen-
esis and tumor growth of both EphB4 and EphB4
tumors, likely by modulating the vascular response. As
humanized versions of these antibodies maintain tumor-
inhibitory functions, these antibodies are strong candi-
dates for clinical applications.
HRGP (Histadine-Rich Glycoprotein)
Modulates Angiogenesis
Interaction of CD36, a cell surface receptor expressed on
microvascular endothelial cells, with the soluble anti-angio-
genic domain of brain angiogensis inhibitor 1 (Vstat120)
elicits an anti-angiogenic response. Klenotic et al (Am J
Pathol 2010, 176:2039–2050) discovered that Vstat120
binding to CD36 activated a pro-apoptotic pathway,
which could be blocked by HRGP through HRGP–
Vstat120 binding. The HRGP–Vstat120 interaction re-
stored endothelial cell migration and tube formation and
increased brain tumor growth with corresponding in-
creases in tumor vascularity. Indeed, HRGP expression
levels were increased in human brain cancers, indicating
that this angiogenic axis could provide a therapeutic
target for anti-angiogenic cancer therapies.
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